Tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine-1-carboxylate → tert-Butyl 4-(7-fluoro-2-(1-(5-propylpyrimidin-2-yl)piperidin-4-yl)-2,3-dihydrobenzofuran-5-yl)-5,6-dihydropyridine-1(2H)-carboxylate

Participants

Reaction Steps

Compound 3G was prepared from Compound 3F and tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate in a similar manner to the procedure described for Compound 1I in Example 1. 1H NMR (500 MHz, CDCl3) δ ppm 8.15 (s, 2 H), 6.96 (s, 1 H), 6.92 (d, J=12.1 Hz, 1 H), 5.91 (br. s., 1 H), 4.81 (dd, J=13.3, 1.2 Hz, 2 H), 4.61-4.71 (m, 1 H), 4.04 (d, J=1.9 Hz, 2H), 3.61 (t, J=5.6 Hz, 2 H), 3.24 (dd, J=15.7, 9.1 Hz, 1 H), 3.04 (dd, J=15.7, 8.3 Hz, 1 H), 2.78-2.91 (m, J=12.8, 12.8, 6.1, 2.8 Hz, 2 H), 2.34-2.50 (m, 4 H), 2.01-2.09 (m, 1 H), 1.91-2.01 (m, 1 H), 1.70-1.79 (m, 1 H), 1.53-1.62 (m, 2 H), 1.49 (s, 9 H), 1.32-1.44 (m, 2 H), 0.93 (t, J=7.3 Hz, 3 H). 19F NMR (471 MHz, CDCl3) δ ppm −138.98. LC/MS (m/z)=523 (M+H)+.

Provenance & Evidence